{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:34:03Z","timestamp":1793345643230,"version":"4.5.0"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Councils of UK Research and Innovation","award":["MR\/W030578\/1"],"award-info":[{"award-number":["MR\/W030578\/1"]}]},{"DOI":"10.13039\/100013281","name":"JPIAMR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UKRI","doi-asserted-by":"publisher","award":["SIPF 674 36348"],"award-info":[{"award-number":["SIPF 674 36348"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Resistance to \u03b2-lactam antibiotics, including carbapenems, mediated by metallo-\u03b2-lactamases (MBLs), including the New Delhi metallo-\u03b2-lactamase (NDM) family, is increasing. No MBL inhibitors are currently approved for clinical use, with most reported MBL inhibitors acting as metal ion chelators at either the Zn(II) ion active site and\/or in solution. The hexokinase inhibitor 3-bromopyruvate (3-BP) has been reported to inhibit NDM-1. This study investigates the ability of 3-BP to restore carbapenem activity against NDM-producing bacterial strains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>The ability of 3-BP to restore meropenem activity was assessed against carbapenem-resistant Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii strains, obtained from clinical and environmental isolates from Tanzania and Malawi. The mechanism of inhibition was investigated using mass spectrometry studies with both biologically relevant sulphur-containing compounds in addition to NDM-1 and NDM-5.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and conclusions<\/jats:title>\n                    <jats:p>3-BP selectively restored the antimicrobial activity of meropenem against resistant strains containing genes encoding NDM-1 or NDM-5 but did not restore the antimicrobial activity of amoxicillin against resistant strains containing genes encoding serine \u03b2-lactamases. Mass spectrometry studies with NDM-1 and NDM-5 support a mechanism involving covalent reaction of 3-BP with an active site cysteine residue. These results will promote work on the development of covalently reacting MBL inhibitors, a strategy that has been successful for inhibition of the nucleophilic serine \u03b2-lactamases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlag177","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:39:17Z","timestamp":1786448357000},"source":"Crossref","is-referenced-by-count":1,"title":["Covalent inhibition of New Delhi metallo-\u03b2-lactamases NDM-1 and NDM-5 by 3-bromopyruvate"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9165-0747","authenticated-orcid":false,"given":"Jack K","family":"Bradley","sequence":"first","affiliation":[{"name":"Department of Tropical Disease Biology, Liverpool School of Tropical Medicine Centre for Drugs and Diagnostics, , Liverpool ,","place":["UK"]},{"name":"Department of Chemistry, University of Liverpool , Liverpool ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina Calvopina","family":"Tapia","sequence":"additional","affiliation":[{"name":"Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Chemistry Research Laboratory , 12 Mansfield Road, Oxford OX1 3TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina J","family":"Moyo","sequence":"additional","affiliation":[{"name":"Department of Tropical Disease Biology, Liverpool School of Tropical Medicine Centre for Drugs and Diagnostics, , Liverpool ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellinor","family":"Shore","sequence":"additional","affiliation":[{"name":"Department of Tropical Disease Biology, Liverpool School of Tropical Medicine Centre for Drugs and Diagnostics, , Liverpool ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nambala","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Liverpool School of Tropical Medicine , Liverpool ,","place":["UK"]},{"name":"Malawi-Liverpool-Wellcome Trust Research Programme (MLW) , Kamuzu University of Health Sciences, Blantyre ,","place":["Malawi"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W David","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Liverpool , Liverpool ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Schofield","sequence":"additional","affiliation":[{"name":"Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Chemistry Research Laboratory , 12 Mansfield Road, Oxford OX1 3TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Tropical Disease Biology, Liverpool School of Tropical Medicine Centre for Drugs and Diagnostics, , Liverpool ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"2026082504515612600_dlag177-B1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1179\/2047773215Y.0000000030","article-title":"Antimicrobial resistance: a global multifaceted phenomenon","volume":"109","author":"Prestinaci","year":"2015","journal-title":"Pathog Glob Health"},{"key":"2026082504515612600_dlag177-B2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"issue":"Pt 2","key":"2026082504515612600_dlag177-B3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1107\/S2052252517000367","article-title":"The mechanism behind the selection of two different cleavage sites in NAG-NAM polymers","volume":"4","author":"Miheli\u010d","year":"2017","journal-title":"IUCrJ"},{"key":"2026082504515612600_dlag177-B4","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems: past, present, and future","volume":"55","author":"Papp-Wallace","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026082504515612600_dlag177-B5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1574-6976.2007.00095.x","article-title":"Penicillin-binding proteins and \u03b2-lactam resistance","volume":"32","author":"Zapun","year":"2008","journal-title":"FEMS Microbiol Rev"},{"key":"2026082504515612600_dlag177-B6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1128\/CMR.00037-09","article-title":"Three decades of \u03b2-lactamase inhibitors","volume":"23","author":"Drawz","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"2026082504515612600_dlag177-B7","doi-asserted-by":"publisher","first-page":"a025247","DOI":"10.1101\/cshperspect.a025247","article-title":"\u03b2-Lactams and \u03b2-lactamase inhibitors: an overview","volume":"6","author":"Bush","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026082504515612600_dlag177-B8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1021\/ar0400241","article-title":"Metallo-\u03b2-lactamases: novel weaponry for antibiotic resistance in Bacteria","volume":"39","author":"Crowder","year":"2006","journal-title":"Acc Chem Res"},{"key":"2026082504515612600_dlag177-B9","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1128\/AAC.45.3.660-663.2001","article-title":"Standard numbering scheme for class B & beta-lactamases","volume":"45","author":"Galleni","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2026082504515612600_dlag177-B10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/nature13445","article-title":"Aspergillomarasmine A overcomes metallo-\u03b2-lactamase antibiotic resistance","volume":"510","author":"King","year":"2014","journal-title":"Nature"},{"key":"2026082504515612600_dlag177-B11","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.tips.2018.03.007","article-title":"The continuing challenge of metallo-\u03b2-lactamase inhibition: mechanism matters","volume":"39","author":"Ju","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"2026082504515612600_dlag177-B12","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3201\/eid1710.110655","article-title":"Global spread of carbapenemase-producing Enterobacteriaceae","volume":"17","author":"Nordmann","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"2026082504515612600_dlag177-B13","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1128\/AAC.00774-09","article-title":"Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India","volume":"53","author":"Yong","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026082504515612600_dlag177-B14","doi-asserted-by":"publisher","first-page":"104588","DOI":"10.1016\/j.meegid.2020.104588","article-title":"Evolving trends of New Delhi metallo-betalactamse (NDM) variants: a threat to antimicrobial resistance","volume":"86","author":"Farhat","year":"2020","journal-title":"Infect Genet Evol"},{"key":"2026082504515612600_dlag177-B15","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/trstmh\/traa173","article-title":"Molecular characterisation of the first New Delhi metallo-\u03b2-lactamase 1-producing Acinetobacter baumannii from Tanzania","volume":"115","author":"Moyo","year":"2021","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2026082504515612600_dlag177-B16","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1107\/S1744309111029654","article-title":"Structure of New Delhi metallo-[beta]-lactamase 1 (NDM-1)","volume":"67","author":"Green","year":"2011","journal-title":"Acta Crystallographica Section F"},{"key":"2026082504515612600_dlag177-B17","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41570-025-00772-w","article-title":"Small but powerful","volume":"9","author":"Stachulski","year":"2025","journal-title":"Nat Rev Chem"},{"key":"2026082504515612600_dlag177-B18","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1007\/s40121-024-01044-8","article-title":"Navigating the current treatment landscape of metallo-\u03b2-lactamase-producing Gram-negative infections: what are the limitations?","volume":"13","author":"Grabein","year":"2024","journal-title":"Infect Dis Ther"},{"key":"2026082504515612600_dlag177-B19","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S1473-3099(20)30868-9","article-title":"The urgent need for metallo-beta-lactamase inhibitors: an unattended global threat","volume":"22","author":"Mojica","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2026082504515612600_dlag177-B20","doi-asserted-by":"publisher","first-page":"105161","DOI":"10.1016\/j.ejps.2019.105161","article-title":"3-Bromopyruvate as a potent covalently reversible inhibitor of New Delhi metallo-\u03b2-lactamase-1 (NDM-1)","volume":"142","author":"Kang","year":"2020","journal-title":"Eur J Pharm Sci"},{"key":"2026082504515612600_dlag177-B21","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1039\/C5CC02594J","article-title":"Ebselen as a potent covalent inhibitor of New Delhi metallo-\u03b2-lactamase (NDM-1)","volume":"51","author":"Chiou","year":"2015","journal-title":"Chem Commun"},{"key":"2026082504515612600_dlag177-B22","doi-asserted-by":"publisher","first-page":"12398","DOI":"10.1021\/acs.jmedchem.6c00314","article-title":"The New Delhi metallo-\u03b2-lactamase-1 covalent inhibitors derived from cephalexin effectively reverse meropenem resistance","volume":"69","author":"Liu","year":"2026","journal-title":"J Med Chem"},{"key":"2026082504515612600_dlag177-B23","doi-asserted-by":"publisher","first-page":"112573","DOI":"10.1016\/j.ejmech.2020.112573","article-title":"Structure-based design of covalent inhibitors targeting metallo-\u03b2-lactamases","volume":"203","author":"Chen","year":"2020","journal-title":"Eur J Med Chem"},{"key":"2026082504515612600_dlag177-B24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.molonc.2008.01.003","article-title":"3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs","volume":"2","author":"Ihrlund","year":"2008","journal-title":"Mol Oncol"},{"key":"2026082504515612600_dlag177-B25","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1021\/acschembio.8b00743","article-title":"Bioorthogonal profiling of a cancer cell proteome identifies a large set of 3-bromopyruvate targets beyond glycolysis","volume":"13","author":"Darabedian","year":"2018","journal-title":"ACS Chem Biol"},{"key":"2026082504515612600_dlag177-B26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10863-012-9422-7","article-title":"Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug","volume":"44","author":"Cardaci","year":"2012","journal-title":"J Bioenerg Biomembr"},{"key":"2026082504515612600_dlag177-B27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10863-012-9417-4","article-title":"A translational study \u201ccase report\u201d on the small molecule \u201cenergy blocker\u201d 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside","volume":"44","author":"Ko","year":"2012","journal-title":"J Bioenerg Biomembr"},{"key":"2026082504515612600_dlag177-B28","doi-asserted-by":"publisher","first-page":"752535","DOI":"10.3389\/fmicb.2021.752535","article-title":"Structural insights for core scaffold and substrate specificity of B1, B2, and B3 metallo-\u03b2-lactamases","volume":"12","author":"Yun","year":"2021","journal-title":"Front Microbiol"},{"key":"2026082504515612600_dlag177-B29","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"2026082504515612600_dlag177-B30","doi-asserted-by":"publisher","first-page":"e4792","DOI":"10.1002\/pro.4792","article-title":"UCSF ChimeraX: tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Sci"},{"key":"2026082504515612600_dlag177-B31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s44259-024-00051-6","article-title":"Antibiotic susceptibility testing using minimum inhibitory concentration (MIC) assays","volume":"2","author":"Kade\u0159\u00e1bkov\u00e1","year":"2024","journal-title":"NPJ Antimicrob Resist"},{"key":"2026082504515612600_dlag177-B32","doi-asserted-by":"publisher","first-page":"001513","DOI":"10.1099\/jmm.0.001513","article-title":"First identification of bla(NDM-5) producing Escherichia coli from neonates and a HIV infected adult in Tanzania","volume":"71","author":"Manyahi","year":"2022","journal-title":"J Med Microbiol"},{"key":"2026082504515612600_dlag177-B33","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.3389\/fmicb.2020.02118","article-title":"Bacteraemia, malaria, and case fatality among children hospitalized with fever in Dar es Salaam, Tanzania","volume":"11","author":"Moyo","year":"2020","journal-title":"Front Microbiol"},{"key":"2026082504515612600_dlag177-B34","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.pharep.2015.11.007","article-title":"Anticancer agent 3-bromopyruvic acid forms a conjugate with glutathione","volume":"68","author":"Sadowska-Bartosz","year":"2016","journal-title":"Pharmacol Rep"},{"key":"2026082504515612600_dlag177-B35","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/jnr.23474","article-title":"3-bromopyruvate inhibits glycolysis, depletes cellular glutathione, and compromises the viability of cultured primary rat astrocytes","volume":"93","author":"Ehrke","year":"2015","journal-title":"J Neurosci Res"},{"key":"2026082504515612600_dlag177-B36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1476-4598-12-152","article-title":"Tumor glycolysis as a target for cancer therapy: progress and prospects","volume":"12","author":"Ganapathy-Kanniappan","year":"2013","journal-title":"Mol Cancer"},{"key":"2026082504515612600_dlag177-B37","first-page":"4909","article-title":"Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death","volume":"29","author":"Ganapathy-Kanniappan","year":"2009","journal-title":"Anticancer Res"},{"key":"2026082504515612600_dlag177-B38","doi-asserted-by":"publisher","first-page":"5952","DOI":"10.1128\/AAC.05108-11","article-title":"A novel variant, NDM-5, of the New Delhi metallo-\u03b2-lactamase in a multidrug-resistant Escherichia coli ST648 isolate recovered from a patient in the United Kingdom","volume":"55","author":"Hornsey","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026082504515612600_dlag177-B39","doi-asserted-by":"publisher","first-page":"e01849-17","DOI":"10.1128\/AAC.01849-17","article-title":"Clinical evolution of New Delhi metallo-\u03b2-lactamase (NDM) optimizes resistance under Zn(II) deprivation","volume":"62","author":"Bahr","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026082504515612600_dlag177-B40","doi-asserted-by":"publisher","first-page":"100918","DOI":"10.1016\/j.jbc.2021.100918","article-title":"Aspergillomarasmine A inhibits metallo-\u03b2-lactamases by selectively sequestering Zn2+","volume":"297","author":"Sychantha","year":"2021","journal-title":"J Biol Chem"},{"key":"2026082504515612600_dlag177-B41","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1021\/bi010933n","article-title":"Exploring the role and the binding affinity of a second zinc equivalent in B. cereus metallo-\u03b2-lactamase","volume":"41","author":"Rasia","year":"2002","journal-title":"Biochemistry"},{"key":"2026082504515612600_dlag177-B42","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.jmb.2006.01.003","article-title":"Crystal structure of Pseudomonas aeruginosa SPM-1 provides insights into variable zinc affinity of metallo-\u03b2-lactamases","volume":"357","author":"Murphy","year":"2006","journal-title":"J Mol Biol"},{"key":"2026082504515612600_dlag177-B43","doi-asserted-by":"publisher","first-page":"e24621","DOI":"10.1371\/journal.pone.0024621","article-title":"Structure of apo-and monometalated forms of NDM-1\u2014a highly potent carbapenem-hydrolyzing metallo-\u03b2-lactamase","volume":"6","author":"Kim","year":"2011","journal-title":"PLOS ONE"},{"key":"2026082504515612600_dlag177-B44","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.3390\/molecules25174031","article-title":"Peptidyl fluoromethyl ketones and their applications in medicinal chemistry","volume":"25","author":"Citarella","year":"2020","journal-title":"Molecules"},{"key":"2026082504515612600_dlag177-B45","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1021\/bi00662a014","article-title":"Binding of chloromethyl ketone substrate analogs to crystalline papain","volume":"15","author":"Drenth","year":"1976","journal-title":"Biochemistry"},{"key":"2026082504515612600_dlag177-B46","doi-asserted-by":"publisher","first-page":"6539","DOI":"10.1074\/jbc.272.10.6539","article-title":"Structure of recombinant human CPP32 in complex with the tetrapeptide acetyl-Asp-Val-Ala-Asp fluoromethyl ketone","volume":"272","author":"Mittl","year":"1997","journal-title":"J Biol Chem"},{"key":"2026082504515612600_dlag177-B47","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1021\/cr010182v","article-title":"Irreversible inhibitors of serine, cysteine, and threonine proteases","volume":"102","author":"Powers","year":"2002","journal-title":"Chem Rev"},{"key":"2026082504515612600_dlag177-B48","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1747-0285.2008.00679.x","article-title":"Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CLpro","volume":"72","author":"Bacha","year":"2008","journal-title":"Chem Biol Drug Des"},{"key":"2026082504515612600_dlag177-B49","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1021\/cr950025u","article-title":"Cysteine proteases and their inhibitors","volume":"97","author":"Otto","year":"1997","journal-title":"Chem Rev"},{"key":"2026082504515612600_dlag177-B50","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1039\/D0MD00154F","article-title":"Covalent inhibitors: a rational approach to drug discovery","volume":"11","author":"Sutanto","year":"2020","journal-title":"RSC Med Chem"},{"key":"2026082504515612600_dlag177-B51","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"2026082504515612600_dlag177-B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drudis.2015.05.005","article-title":"Covalent inhibitors in drug discovery: from accidental discoveries to rational design","volume":"1","author":"Bauer","year":"2015","journal-title":"Drug Discov Today"},{"key":"2026082504515612600_dlag177-B53","doi-asserted-by":"publisher","first-page":"14210","DOI":"10.1021\/ja505194w","article-title":"Advances in covalent inhibitor design","volume":"123","author":"Krishnan","year":"2023","journal-title":"J Am Chem Soc"},{"key":"2026082504515612600_dlag177-B54","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/med.22084","article-title":"Advances in reversible covalent kinase inhibitors","volume":"45","author":"Zhao","year":"2025","journal-title":"Med Res Rev"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/4\/dlag177\/70775635\/dlag177.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/4\/dlag177\/70775635\/dlag177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:52:06Z","timestamp":1787647926000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlag177\/8769935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlag177","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"dlag177"}}